Pulse Biosciences Schedules Third Quarter 2023 Financial Results Conference Call for November 13, 2023

Rhea-AI Summary

Pulse Biosciences (PLSE) will report Q3 2023 financial results on November 13, 2023, after market close. The company focuses on using its nsPFA technology for the treatment of atrial fibrillation. A conference call will be held at 1:30pm PT / 4:30pm ET, and a webcast will be available.

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced it will report financial results for the third quarter of 2023 after market close on Monday, November 13, 2023. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET.

Investors interested in listening to the conference call may do so by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers. A live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where nsPFA could have a profound positive impact on healthcare for both patients and providers.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231030281954/en/

Investor Contacts:

Pulse Biosciences

Kevin Danahy, CEO

510.241.1077

IR@pulsebiosciences.com

or

Gilmartin Group

Philip Trip Taylor

415.937.5406

philip@gilmartinir.com

Source: Pulse Biosciences, Inc.

FAQ

When will Pulse Biosciences report its Q3 2023 financial results?

Pulse Biosciences will report its Q3 2023 financial results on November 13, 2023, after market close.

What is Pulse Biosciences primarily focused on?

Pulse Biosciences is primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation.

When is the conference call for investors?

The conference call for investors will begin at 1:30pm PT / 4:30pm ET.

How can investors listen to the conference call?

Investors can listen to the conference call by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers.

Will there be a webcast of the event?

Yes, there will be a live and recorded webcast of the event available at http://investors.pulsebiosciences.com/.